The contract development and manufacturing organization (CDMO) industry has seen significant advancements and partnerships as of January 2025. With a focus on large molecules and advanced therapies, this article delves into the latest developments, highlighting key trends, common themes, and
January 13, 2025
Aspect Biosystems, a pioneer in the field of bioprinted tissue therapeutics, recently closed a $115 million Series B financing round aimed at advancing its groundbreaking technology in regenerative medicine. This achievement, led by Dimension and supported by investors such as Novo Nordisk and
January 13, 2025
The Blood and Cell Advocacy Register (BCAR) is a newly launched consortium that aims to revolutionize the development and commercialization of advanced therapy medicinal products (ATMPs). Formed in December 2024, BCAR brings together experts and organizations from the blood and cell industries to
January 10, 2025
The advancements in muscle regeneration technology by Swiss biotech company MUVON Therapeutics are making waves, especially in the realm of treating stress urinary incontinence in women. This breakthrough holds the potential to improve the quality of life for millions while extending healthspan.
January 10, 2025
In the laboratories of Matricelf, located in Nes Ziona, Israel, an innovative development endeavor is underway, holding the potential to revolutionize the treatment of spinal cord injuries. Established in 2019 by Professor Tal Dvir and Dr. Alon Sinai, Matricelf is at the forefront of creating
January 7, 2025
The field of biochemical engineering is witnessing an innovative approach with the development of fine-bubble engineering techniques. By focusing on the manipulation of both nanobubbles (NBs) and microbubbles (MBs), researchers aim to improve the efficiency and effectiveness of various bioprocess
January 7, 2025
